Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398857 | 0.89 | L3MBTL1 (0.68) | ALDH1A1L3MBTL1TBXAS1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL5656951 | 0.88 | L3MBTL1 (0.66) | ALDH1A1L3MBTL1TBXAS1SMN1; SMN2NPC1 | |
| SCHEMBL9370041 | 0.84 | EGLN3 (0.59) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL4399230 | 0.84 | ALDH1A1 (0.54) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL16610099 | 0.84 | EGLN3 (0.58) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL29058772 | 0.81 | ALDH1A1 (0.57) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL16807523 | 0.81 | ALDH1A1 (0.55) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL13853598 | 0.81 | QPCT (0.55) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL15014468 | 0.81 | KDM4E (0.55) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL4156721 | 0.81 | ALDH1A1 (0.51) | EGLN3ALDH1A1L3MBTL1TBXAS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017168451-A1 | DERIVATIVES OF IMIDAZOLE AND BENZIMIDAZOLE, METHOD OF PREPARATION AND USE THEREOF | SHIV NADAR UNIVERSITY (IN) | 2017-10-05 | — | — | WO | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | EGLN3 2729/4885ALDH1A1 1738/4885L3MBTL1 2478/4885 |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | EGLN3 738/4885ALDH1A1 1036/4885L3MBTL1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.